Details for New Drug Application (NDA): 022396
✉ Email this page to a colleague
The generic ingredient in DYLOJECT is diclofenac sodium. There are forty-seven drug master file entries for this compound. One hundred and twenty-six suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.
Summary for 022396
Tradename: | DYLOJECT |
Applicant: | Javelin Pharms Inc |
Ingredient: | diclofenac sodium |
Patents: | 1 |
Formulation / Manufacturing: | see details |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 37.5MG/ML (37.5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Dec 23, 2014 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Mar 22, 2027 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | MANAGEMENT OF PAIN |
Expired US Patents for NDA 022396
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Javelin Pharms Inc | DYLOJECT | diclofenac sodium | SOLUTION;INTRAVENOUS | 022396-001 | Dec 23, 2014 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription